One small* 34 mg capsule formulation1
*Actual size is 14.3 mm x 5.3 mm.Learn more
Approximately 50% of patients with PD may develop hallucinations and/or delusions over the course of their disease3
THE TIME FOR NUPLAZID IS NOW
NUPLAZID is the only FDA-approved therapy for the treatment of hallucinations and delusions associated with PD psychosis1,2
NUPLAZID has a demonstrated safety profile in elderly patients with PD psychosis1
- In the 6-week studies, 80% of patients in NUPLAZID clinical studies were aged 65 years or older*
- No differences in safety were reported based on age, gender, or MMSE score
– 27% of patients had MMSE 21-24
- The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%)
In the clinical studies, the maximum age of patients on NUPLAZID was 85 years old vs 90 years old for placebo.4
MMSE=Mini-Mental State Examination.
Important Safety Information for NUPLAZID (pimavanserin)
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death
- NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis
NUPLAZID significantly reduced the frequency and/or severity of hallucinations and delusions associated with PD psychosis at 6 weeks vs placebo (Primary Endpoint)1
NUPLAZID showed signs of improvement from baseline as early as 2 weeks, with significant reductions at Weeks 4 & 61,5
Results from a Phase 3, randomized, multicenter, double-blind, placebo-controlled, parallel-group study of patients with PD psychosis (N=199). Primary endpoint was change from baseline in the 9-item SAPS-PD. PD medications were required to be stable for at least 30 days prior to study entry and throughout the study period. Mean baseline score was 15.9 for NUPLAZID and 14.7 for placebo.1,5 The mean age of patients enrolled in the clinical study with NUPLAZID was 72 years. While the primary endpoint was designed to measure change from baseline to Week 6, a statistically significant difference between NUPLAZID and placebo was observed at Week 4 (P=0.0369) and again at Week 6 (P=0.0014).5
LSM=least squares mean; SAPS=Scale for Assessment of Positive Symptoms; SE=standard error.
Proposed mechanism of action for NUPLAZID1*
The precise mechanism of action of NUPLAZID in the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis is unclear. However, the effect of NUPLAZID could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.
NUPLAZIDconnect™ makes it easy to start your patients on NUPLAZID and provides the support they deserve.
Get your patients started on NUPLAZID right away with a free 14-day supply.*
Appropriate patients must be enrolled in NUPLAZIDconnect to be eligible for the free 14-day supply of NUPLAZID. NUPLAZIDconnect patient eligibility and terms and conditions apply.